Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
REPEATED ADMINISTRATION OF A F(AB')2 FRAGMENT OF AN ANTITUMOR NECROSIS FACTOR-ALPHA MONOCLONAL-ANTIBODY IN PATIENTS WITH SEVERE SEPSIS - EFFECTS ON THE CARDIOVASCULAR-SYSTEM AND CYTOKINE LEVELS
Autore:
BOEKSTEGERS P; WEIDENHOFER S; ZELL R; PILZ G; HOLLER E; ERTEL W; KAPSNER T; REDL H; SCHLAG G; KAUL M; KEMPENI J; STENZEL R; WERDAN K;
Indirizzi:
UNIV MUNICH,KLINIKUM GROSSHADERN,MED KLIN 1,DEPT INTERNAL MED 1,MARCHIONINISTR 15,P1377 W-8000 MUNICH 70 GERMANY UNIV MUNICH,KLINIKUM GROSSHADERN,DEPT INTERNAL MED 3 W-8000 MUNICH 70GERMANY UNIV MUNICH,KLINIKUM GROSSHADERN,DEPT SURG W-8000 MUNICH 70 GERMANY UNIV MUNICH,DEPT MED INFORMAT BIOMETRY & EPIDEMIOL W-8000 MUNICH 2 GERMANY LUDWIG BOLTZMANN INST EXPTL & CLIN TRAUMATOL VIENNA AUSTRIA KNOLL AG,DEPT ONKOL & IMMUNOL W-6700 LUDWIGSHAFEN GERMANY
Titolo Testata:
Shock
fascicolo: 4, volume: 1, anno: 1994,
pagine: 237 - 245
SICI:
1073-2322(1994)1:4<237:RAOAFF>2.0.ZU;2-6
Fonte:
ISI
Lingua:
ENG
Soggetto:
HUMAN SEPTIC SHOCK; NITRIC-OXIDE; APACHE-II; ENDOTOXIN; THERAPY; CELLS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
35
Recensione:
Indirizzi per estratti:
Citazione:
P. Boekstegers et al., "REPEATED ADMINISTRATION OF A F(AB')2 FRAGMENT OF AN ANTITUMOR NECROSIS FACTOR-ALPHA MONOCLONAL-ANTIBODY IN PATIENTS WITH SEVERE SEPSIS - EFFECTS ON THE CARDIOVASCULAR-SYSTEM AND CYTOKINE LEVELS", Shock, 1(4), 1994, pp. 237-245

Abstract

In an uncontrolled clinical trial the effects of repeated administration of the F(ab')2 fragment of a murine monoclonal anti-tumor necrosisfactor alpha (TNFalpha)-antibody (MAK 195F) on cytokine levels and the cardiovascular system were studied in 20 patients with severe sepsis. Patients were treated with a total of 11 single dosages of the anti-TNFalpha-antibody intravenously over 5 days using either 1 mg/kg (n = 10) or 3 mg/kg (n = 10). The anti-TNFalpha-antibody was well toleratedin all patients without signs of toxicity and without development of anti-murine antibodies. As assessed by cytokine levels (TNFalpha, Interleukin-6) and hemodynamics there was no evidence that the higher dosage of the anti-TNFalpha-antibody (3 mg/kg per dose) was more effectivethan the lower dosage (1 mg/kg per dose). Comparison of our data withrecent data from phase I or II trials using a complete murine monoclonal anti-TNFalpha-antibody suggest that the F(ab')2 fragments of the murine monoclonal anti-TNFalpha-antibody may be of similar efficacy. Definitive conclusions, however, with respect to improvement of mortality and improvement of the cardiovascular system, await the results of larger ongoing placebo-controlled trials.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 15/08/20 alle ore 18:40:42